Caitong International Asset Management Co., LTD Allogene Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 150 shares of ALLO stock, worth $306. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 150
-0.0%
Holding current value
$306
Previous $320,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
178Shares Held
143MCall Options Held
37.5KPut Options Held
77.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$38.2 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$33.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$22.2 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$16.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$14.8 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $293M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...